ATAGI statement about the need for additional doses of COVID-19 vaccines
The Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement about the need for additional doses of COVID-19 vaccines.
The statement strongly recommends maximising first and second dose vaccine uptake across the community without delay in line with current prioritisation and outbreak response strategies and that two doses of any of the vaccines available in Australia have been shown to protect an individual from COVID-19 and its complications, as well as protecting the community.
ATAGI continues to closely monitor local and international data about the frequency and severity of COVID-19 in fully vaccinated individuals as well as reviewing the international data on the efficacy, effectiveness and safety of additional doses for specific high-risk patient populations, including immunocompromised individuals, and the population more generally. These data will inform future strategies regarding additional vaccine doses.
Additional doses can be defined as:
- Third doses: Additional COVID-19 doses required as part of the primary course to reach a comparable (optimal) level of protection
- Booster dose: Additional COVID-19 doses required at a broader population level, to optimise protection due to waning of immunity (loss of protection) over time, with booster doses also leading to improved immune memory.
To read the statement in full, please click the link below:
ATAGI statement about the need for additional doses of COVID-19 vaccines
Webinar recording now available: The Alfred community information session on COVID-19 vaccines
A webinar recording is now available from The Alfred’s community information session on COVID-19 vaccines which was held on Tuesday 21 September.
In this session, Allen Cheng and Associate Professor Nigel Crawford discuss in detail the COVID-19 vaccines, including the safety and efficacy in children over 12 years old, as well as answer questions from the community.
The full recording is available on The Alfred channels or the MVEC Facebook page via the links below:
The Alfred community discussion 21 September
MVEC Facebook page
ABC 新闻：辉瑞申请批准用于 5 至 11 岁儿童的 COVID-19 疫苗
这项备受期待的试验涉及 2,000 多名儿童，研究了辉瑞和 BioNTech COVID-19 疫苗对 5 至 11 岁儿童的有效性和安全性，初步结果表明该疫苗是安全的，并建立了针对该病毒的强大抗体反应。
尽管初步结果令人鼓舞，但在美国和澳大利亚正式推出针对 5 至 11 岁儿童的疫苗还需要一段时间。一旦试验分析完成，为了获得批准，公司需要向 FDA 提供正式的免疫“桥接”研究，该研究提供基于数据的证据，证明儿童产生的相同抗体水平已被证明具有保护作用在年龄较大的儿童和青少年中。结果将提交给美国食品和药物管理局 (FDA) 进行审查和紧急使用授权。
要阅读全文，请点击以下链接：
https://www.abc.net.au/news/2021-09-21/pfizer-covid-19-vaccine-5-to-11-year-old/100478362
Chest Pain Guideline updated in MVEC myocarditis/pericarditis following mRNA vaccines pages
We have updated our COVID-19 FAQs regarding myocarditis/pericarditis following mRNA vaccines page to include the new Chest Pain Guidelines.
PREDICT and ACEM, in consultation with the Australian Technical Advisory Group on Immunisation (ATAGI), the NZ Immunisation Advisory Centre, and the Cardiac Society of Australia and New Zealand (CSANZ) have developed a brief guideline on an approach to the initial assessment and workup of children and adolescents presenting to the ED with vaccine-related symptoms.
To read the guidelines, please refer to the following MVEC pages:
MVEC: COVID-19 FAQs page: myocarditis/pericarditis following mRNA vaccines
MVEC: Myocarditis/pericarditis following mRNA vaccines reference page
PHN Webinar: Primary Care Management of Myocarditis and Pericarditis After mRNA COVID-19 Vaccines
The PHN will be hosting a webinar for GPs on Tuesday 28 September featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford, Dr. Scott Parsons GP Clinical Editor, HealthPathways Melbourne and Dr. Bryn Jones Deputy Director of Cardiology, Royal Children’s Hospital. The topic for the webinar is Primary Care Management of Myocarditis and Pericarditis After mRNA COVID-19 Vaccines 并将涵盖：
- Identification and assessment of myocarditis and pericarditis following mRNA COVID-19 Vaccination
- Understanding management and referral guidelines
有关注册的更多信息和详细信息，请访问以下链接：
PHN webinar: Primary Care Management of Myocarditis and Pericarditis After mRNA COVID-19 Vaccines
New resource: The MVEC Conversation: myocarditis/pericarditis following mRNA vaccines
继我们的 CVU 迷你虚拟活动之后： 心脏问题：与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎, 墨尔本疫苗教育中心很高兴地宣布我们的最新资源 MVEC 对话：mRNA 疫苗后的心肌炎/心包炎。
该视频播客深入探讨了这一特殊关注的不良事件 (AESI)，特邀嘉宾 Tom Shimabukuro 博士是佐治亚州亚特兰大疾病控制与预防中心 (CDC) 免疫安全办公室副主任，与 Daryl Cheng 博士和 Nigel Crawford 副教授的对话。
To find out more about this resource, please visit our MVEC Events page.
ABC News: Israel is struggling with COVID-19, despite high vaccination rates. What lessons can Australia learn?
Due to an early and rapid vaccine roll-out, Israel was leading the way for COVID-19 immunisation, with nearly 80 per cent of its citizens aged 12 and over fully inoculated by June. However, cases numbers and rates of hospitalisations began to rapidly rise again by late June with Israel recording its highest single-day spike with 16,011 new infections on September 1.
As Australia works its way towards reopening, this article discusses the important lessons we can learn from Israel's vaccination program. Professor Lewin, Director of The Doherty Institute commented "What we've learned from [Israel], and what's consistent with the modelling is that even at 80 per cent, you need to have some public health measures in place to contain the transmission,"
要阅读全文，请点击以下链接：
ABC News: Israel is struggling with COVID-19, despite high vaccination rates. What lessons can Australia learn?
可用于护士免疫课程的英联邦资助名额
具有一年临床经验的注册护士 (RN) 名额有限，可以免费完成联邦资助的护士免疫程序短期课程（有条件）。
免疫接种（Nurse immuniser）短期课程是基于 国家卫生专业人员免疫教育框架 (2017) 并已获得国家健康教育机构的认可 澳大利亚健康教育服务 (HESA).
要了解有关本课程的更多信息，请单击下面的链接。请注意一些分配已经用完。
墨尔本大学：免疫接种（Nurse immuniser）短期课程
基准组免疫认可途径
ABC News: Another 1 million Moderna COVID-19 vaccines doses coming to Australia after EU deal
1 million doses of the Moderna vaccine which have been secured from European nations are to be sent directly to community pharmacies across the country this week. The announcement is in line with advice from the Australian Technical Advisory Group on Immunisation (ATAGI).
On announcing the latest deal, the government has confirmed that there was now enough vaccine for everyone still waiting for a jab to be offered one in October. In addition to this, from the week of September 20, approximately 1,800 community pharmacies across the country will receive Moderna doses, with an additional 1,800 to receive Moderna doses after that.
To read the article in full, click on the link below.
ABC News: Another 1 million Moderna COVID-19 vaccines doses coming to Australia after EU deal
The Age: ‘Jabba the Bus’ to take regional vaccination drive onto the road
Jabba the bus brings about exciting news for COVID-19 vaccination in regional Victoria. The mobile vaccine hub will deliver essential AstraZeneca and Pfizer vaccines to isolated residents of regional Victoria. The focus will be on the City of Greater Shepparton as well as Moira, Benalla, Strathbogie, Mitchell, Mansfield Murrindindi and Campaspe.
A high sense of urgency perpetuated the need for the mobile vaccination hub following a large COVID-19 outbreak in Shepparton which forced more than 20 000 people into isolation, including more than 500 staff from Goulburn Valley Health. Goulburn Valley Health Chief executive Matt Sharp indicated that currently, only 45 per cent of people had received even their first dose of a COVID-19 vaccine, while an increasingly more alarming rate of just 26 per cent received their second dose.
The mobile vaccination station, which is the first service of its’ kind in the state represents a promising opportunity to increase vaccine uptake amongst groups of people who otherwise may not have access to the vaccine and includes easy accessibility for people with disabilities.
Full article:
The Age: The Age: ‘Jabba the Bus’ to take regional vaccination drive onto the road